CLRB Stock Quote Price and Forecast | CNN

CLRB

Cellectar Biosciences, Inc.

Key terms

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

May 15 2:05pm ET Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline by TipRanks May 14 6:42am ET Cellectar Biosciences reports Q1 EPS (74c), consensus ($1.00) by TipRanks Mar 28 3:25pm ET Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials by TipRanks Mar 28 8:18am ET Cellectar Biosciences price target raised to $28 from $20 at Roth MKM by TipRanks Mar 28 7:50am ET Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS) by TipRanks Mar 28 7:43am ET Cellectar Biosciences price target raised to $12 from $11 at Oppenheimer by TipRanks Mar 25 8:00am ET Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024 by TipRanks Mar 04 11:55am ET Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Acquisition Potential by TipRanks Mar 04 11:50am ET Cellectar Bio reports ‘impressive’ efficacy in Phase 1 trial, says Roth MKM by TipRanks Mar 04 6:43am ET Cellectar Biosciences reports results from Phase 1 study of iopofosine I 131 by TipRanks

No recent press releases are available for CLRB

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Dave Calhoun, chief executive officer of Boeing Co., center right, on Capitol Hill in Washington, DC, US, on Wednesday, Jan. 24, 2024. The company is working to assure airline customers and the Federal Aviation Administration that its jets are safe after a January 5 accident, which involved a faulty door panel on a 737 Max 9 aircraft operated by Alaska Airlines.

Samuel Corum/Bloomberg/Getty Images

Boeing shareholders vote to approve $33 million CEO pay package

ZHANGYE, CHINA - APRIL 16, 2024 - Workers check photovoltaic panels before packing at the New Material 800MW high-efficiency photovoltaic module production line in Zhangye city, Gansu province, China, April 16, 2024.

CFOTO/Future Publishing/Getty Images

Biden’s tariffs on Chinese imports are boosting these beaten-down stocks

Traders work on the floor of the New York Stock Exchange on May 16, 2024. Wall Street is buoyed by hopes the Federal Reserve will pull back on its restrictive monetary policy after data showed inflation is beginning to ease.

Spencer Platt/Getty Images

Dow briefly tops 40,000 for first time but ends the day lower

Shoppers at a Walmart store in Secaucus, New Jersey, US, on Tuesday, March 5, 2024. Walmart is revamping more than 800 store locations and adding high-end products.

Gabby Jones/Bloomberg/Getty Images

Walmart’s business surges as shoppers hunt for low prices